T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy

Wang,Fuhai; Dong,Xiaofeng; Xiu,Peng; Zhong,Jingtao; Wei,Honglong; Xu,Zongzhen; Li,Tao; Liu,Feng; Sun,Xueying; Li,Jie

doi:10.3892/or.2014.3653

T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy

Authors:
- Fuhai Wang
- Xiaofeng Dong
- Peng Xiu
- Jingtao Zhong
- Honglong Wei
- Zongzhen Xu
- Tao Li
- Feng Liu
- Xueying Sun
- Jie Li
View Affiliations

Affiliations: Department of General Surgery, Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China, Department of General Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, P.R. China, Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
Published online on: December 5, 2014 https://doi.org/10.3892/or.2014.3653
Pages: 675-684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is required for the invasion, metastasis and chemoresistance of tumor cells. In addition to vascular endothelial cell growth factor (VEGF), angiopoietin-2 (Ang2) is considered to be a promising target for anti-angiogenic therapy. The T7 peptide, an active fragment of full-length tumstatin [the noncollagenous 1 domain of the type IV collagen α3 chain, α3(IV)NC1], has equivalent anti-angiogenic activity to that of full-length tumstatin. This study aimed to explore the mechanisms of the T7 peptide in the regulation of Ang2 expression in endothelial cells (ECs) as well as inhibition of angiogenesis and invasion of hepatocellular carcinoma cells. We also examined the role of autophagy in angiogenesis. Human umbilical vein endothelial cells (HUVECs) were incubated with endothelial cell medium (ECM)-2 in a hypoxia chamber to mimic hypoxic conditions. The recombinant T7 peptide inhibited the cell viability, tube formation and induced apoptosis of the HUVECs. The T7 peptide downregulated the protein expression of Ang2 by inhibiting phosphorylation of AKT under hypoxic conditions. The migration of HUVECs and invasion of HepG2 cells were inhibited by the T7 peptide via inhibition of Ang2 expression. EC autophagy was induced by the T7 peptide. Inhibition of autophagy enhanced the anti‑angiogenic activity of the T7 peptide by increasing EC apoptosis. In vivo, immunohistochemistry of VE-cadherin and CD31 showed that angiogenesis was decreased significantly by the T7 peptide in a nude mouse xenogeneic tumor model. In conclusion, the T7 peptide inhibited angiogenesis and exerted its antitumor effects by inhibition of Ang2, phosphorylation of AKT and matrix metalloproteinase-2 (MMP-2) regulated by Ang2. Furthermore, inhibition of autophagy may significantly enhance the anti-angiogenic activity of the T7 peptide.

View Figures

View References

1	Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev of Anticancer Ther. 12:1347–1357. 2012. View Article : Google Scholar
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
4	Almog N, Ma L, Schwager C, et al: Consensus microRNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One. 7:e440012012. View Article : Google Scholar
5	Welker MW and Trojan J: Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. World J Gastroenterol. 17:3075–3081. 2011.PubMed/NCBI
6	Edeline J, Boucher E, Rolland Y, et al: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 118:147–156. 2012. View Article : Google Scholar
7	Zhai B and Sun XY: Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013. View Article : Google Scholar : PubMed/NCBI
8	Liang Y, Zheng T, Song R, et al: Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology. 57:1847–1857. 2013. View Article : Google Scholar : PubMed/NCBI
9	Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
10	Miyahara K, Nouso K, Tomoda T, et al: Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 26:1604–1611. 2011. View Article : Google Scholar : PubMed/NCBI
11	Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
12	Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 10:165–177. 2009. View Article : Google Scholar : PubMed/NCBI
13	Saharinen P, Bry M and Alitalo K: How do angiopoietins Tie in with vascular endothelial growth factors? Cur Opin Hematol. 17:198–205. 2010.
14	Boosani CS, Mannam AP, Cosgrove D, et al: Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Blood. 110:1168–1177. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wang W, Xu CX, Hou GS, Chen YG, Xin JX and Liu XX: Downregulation of tumstatin expression by overexpression of ornithine decarboxylase. Oncol Rep. 30:2042–2048. 2013.PubMed/NCBI
16	Colorado PC, Torre A, Kamphaus G, et al: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60:2520–2526. 2000.PubMed/NCBI
17	Maeshima Y, Sudhakar A, Lively JC, et al: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
18	Yamamoto Y, Maeshima Y, Kitayama H, et al: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 53:1831–1840. 2004. View Article : Google Scholar : PubMed/NCBI
19	Glick D, Barth S and Macleod KF: Autophagy: cellular and molecular mechanisms. J Pathol. 221:3–12. 2010. View Article : Google Scholar : PubMed/NCBI
20	Zhu H, Wang D, Zhang L, et al: Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133⁺ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep. 32:935–942. 2014.PubMed/NCBI
21	Dong X, Li R, Xiu P, et al: Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2-dependent and -independent pathways. PLoS One. 9:e928642014. View Article : Google Scholar
22	Roy A and Kolattukudy PE: Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cell Signal. 24:2123–2131. 2012. View Article : Google Scholar : PubMed/NCBI
23	Sachdev U, Cui X, Hong G, et al: High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J Vasc Surg. 55:180–191. 2012. View Article : Google Scholar
24	Nguyen TM, Subramanian IV, Kelekar A and Ramakrishnan S: Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood. 109:4793–4802. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD and Cheng SY: Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res. 66:775–783. 2006. View Article : Google Scholar : PubMed/NCBI
26	Fagiani E and Christofori G: Angiopoietins in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
27	Felcht M, Luck R, Schering A, et al: Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 122:1991–2005. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kim KW, Paul P, Qiao J and Chung DH: Autophagy mediates paracrine regulation of vascular endothelial cells. Lab Invest. 93:639–645. 2013. View Article : Google Scholar : PubMed/NCBI
29	Kimura S, Fujita N, Noda T and Yoshimori T: Monitoring autophagy in mammalian cultured cells through the dynamics of LC3. Methods Enzymol. 452:1–12. 2009. View Article : Google Scholar : PubMed/NCBI
30	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
31	Eikesdal HP, Sugimoto H, Birrane G, et al: Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci USA. 105:15040–15045. 2008. View Article : Google Scholar : PubMed/NCBI
32	Giannotta M, Trani M and Dejana E: VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 26:441–454. 2013. View Article : Google Scholar : PubMed/NCBI
33	Thomas M and Augustin HG: The role of the angiopoietins in vascular morphogenesis. Angiogenesis. 12:125–137. 2009. View Article : Google Scholar : PubMed/NCBI
34	Mazzieri R, Pucci F, Moi D, et al: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 19:512–526. 2011. View Article : Google Scholar : PubMed/NCBI
35	Rini B, Szczylik C, Tannir NM, et al: AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 118:6152–6161. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hashizume H, Falcon BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70:2213–2223. 2010. View Article : Google Scholar : PubMed/NCBI
37	Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res. 16:3618–3627. 2010. View Article : Google Scholar : PubMed/NCBI
38	Wendel HG, De Stanchina E, Fridman JS, et al: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
39	Holopainen T, Saharinen P, D’Amico G, et al: Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst. 104:461–475. 2012. View Article : Google Scholar : PubMed/NCBI
40	Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI